Cautionary statements Statements included herein that are not historical facts are adverse outcomes in legal matters and other disputes, including forward-looking statements.
Such forward-looking statements the combined companys ability to enforce and defend patents involve a number of risks and uncertainties and are subject to change and other intellectual property rights required for its business, at any time.
In the event such risks or uncertainties materialize, could have a material adverse effect on the combined Shires results could be materially adversely affected.
The risks companys revenues, financial condition or results of operations: and uncertainties include, but are not limited to, the following: Shire is undergoing a corporate reorganization and was the subject of an unsuccessful acquisition proposal and the the proposed combination with Baxalta may not be completed consequent uncertainty could adversely affect the combined due to a failure to satisfy certain closing conditions, including companys ability to attract and or retain the highly skilled any shareholder or regulatory approvals or the receipt of personnel needed to meet its strategic objectives: applicable tax opinions: failure to achieve the strategic objectives with respect to Shires disruption from the proposed transaction with Baxalta may acquisition of NPS Pharmaceuticals Inc. or Dyax Corp. Dyax make it more difficult to conduct business as usual or maintain may adversely affect the combined companys financial relationships with patients, physicians, employees or suppliers: condition and results of operations: the combined company may not achieve some or all of the the combined company will be dependent on information anticipated benefits of Baxaltas spin-off from Baxter technology and its systems and infrastructure face certain International, Inc. Baxter and the proposed transaction may risks, including from service disruptions, the loss of sensitive have an adverse impact on Baxaltas existing arrangements with orconfidential information, cyber-attacks and other security Baxter, including those related to transition, manufacturing and breaches or data leakages that could have a material adverse supply services and tax matters: effect on the combined companys revenues, financial condition the failure to achieve the strategic objectives with respect to the or results of operations: proposed combination with Baxalta may adversely affect the the combined company may be unable to retain and hire key combined companys financial condition and results of operations: personnel and or maintain its relationships with customers, products and product candidates may not achieve suppliers and other business partners: commercialsuccess: difficulties in integrating Dyax or Baxalta into Shire may lead to product sales from ADDERALL XR and INTUNIV are subject the combined company not being able to realize the expected togeneric competition: operating efficiencies, cost savings, revenue enhancements, the failure to obtain and maintain reimbursement, or an adequate synergies or other benefits at the time anticipated or at all: and level of reimbursement, by third-party payers in a timely manner other risks and uncertainties detailed from time to time in Shires, for the combined companys products may affect future revenues, Dyaxs or Baxaltas filings with the Securities and Exchange financial condition and results of operations, particularly if there Commission, including those risks outlined in Baxaltas current is pressure on pricing of products to treat rare diseases: Registration Statement on Form S-1, as amended, and on supply chain or manufacturing disruptions may result in declines pages37 to 47 of Shires Annual Report for the year ended in revenue for affected products and commercial traction from December 31, 2015. competitors: regulatory actions associated with product approvals or changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, an increase in operating costs, lost product sales, an interruption ofresearch activities or the delay of new product launches: the successful development of products in various stages of research and development is highly uncertain and requires significant expenditures and time, and there is no guarantee thatthese products will receive regulatory approval: the actions of certain customers could affect the combined companys ability to sell or market products profitably, and fluctuations in buying or distribution patterns by such customers can adversely affect the combined companys revenues, financial condition or results of operations: investigations or enforcement action by regulatory authorities or law enforcement agencies relating to the combined companys activities in the highly regulated markets in which it operates may result in significant legal costs and the payment of substantial compensation or fines: 166 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information Shire plc Report and financial statements For the year ended December 31, 2015 Company Information Directors Contents Dr Flemming Ornskov Directors report 168 Dominic Blakemore Olivier Bohuon Directors responsibilities statement 170 William Burns Auditors report 171 Dr Steven Gillis Dr David Ginsburg Statement of comprehensive income 173 David Kappler Susan Kilsby Statement of financial position 174 Sara Mathew Statement of changes in equity 175 Anne Minto OBE Jeffrey Poulton Statement of cash flows 177 Secretary Accounting policies 178 Bill Mordan Notes to the financial statements 181 Registered office 22 Grenville Street St Helier JE4 8PX Jersey Corporate headquarters 5 Riverwalk Citywest Business Campus Dublin 24 Republic of Ireland Auditor Deloitte LLP London United Kingdom Shire Annual Report 2015 167 Directors report for the year ended December 31, 2015 The Directors present their annual report and the audited financial The net assets of the Company increased from $12,057.3million statements for the year ended December 31, 2015. for the year ended December 31, 2014 to $12,075.8million for the year ended December 31, 2015, primarily as a result of credits Principal activity and business review toshareholders funds in respect of share based compensation Shire plc the Company and its subsidiaries collectively referred awards held by employees in other Group companies partially to as either Shire, or the Group is a leading biotech company offset by the loss recorded in the year.
that focuses on developing and marketing innovative medicines forpatients with rare diseases and other specialty conditions.
Dividends paid and dividend policy The Company paid dividends amounting to $6.8million in the year The Company is the ultimate parent of the Shire group of 2014: $8.9million.
In accordance with IAS arrangements, Shire companies and its principal activity is that of a holding company.
Biopharmaceuticals Holdings paid dividends totaling $127.6million 2014: $112.7million to those shareholders who choose to receive The Group has grown both organically and through acquisition, their dividends from a company tax resident in the UK.
completing a series of major transactions that have brought therapeutic, geographic and pipeline growth and diversification.
A first interim dividend for the six months to June 30, 2015 of 4.21 The Group will continue to conduct its own research and cents 2.69 pence per Ordinary Share, equivalent to 12.63 cents development R&D, focused on rare diseases, as well as per ADS, was paid in October 2015.
The Board has resolved to evaluate companies, products and pipeline opportunities that offer pay a second interim dividend of 22.16 cents 15.56 pence per a strategic fit and have the potential to deliver value to all of the Ordinary Share equivalent to 66.48 cents per ADS for the six Groups stakeholders: patients, physicians, policy makers, payers, months to December 31, 2015. investors and employees.
This is consistent with Shires stated policy of paying a dividend The principal legislation under which the Company operates is semi-annually, set in US cents per ordinary share.
Typically, the Companies Jersey Law 1991 and regulations made thereunder.
first interim payment each year will be higher than the previous The Ordinary Shares of the Company are listed on the London years first interim USD dividend.
Dividend growth for the full year Stock Exchange in the UK, and American Depositary Shares will be reviewed by the Board when the second interim dividend ADS, representing three Ordinary Shares of the Company, isdetermined.
evidenced by an American Depositary Receipt issued by Shires Depositary, Citibank, N. A. are listed on the NASDAQ Global Select Liquidity, cash flow and going concern Market in the USA.
The Company and the Groups business activities, together with the factors likely to affect its future development, performance and Business review position are set out in the Chairmans review, Chief Executive The Business review of the Group can be found in the consolidated Officers review and Review of our Business.
The financial position financial statements and Annual Report and Accounts of the of the Company and the Group, its cash flows, liquidity position Company for the year to December 31, 2015, prepared in accordance and borrowing facilities are described in the Liquidity and capital with United Kingdom Listing Authority requirements the Shire resources section of the Review of our Business of the Shire Annual Report : in the Chairmans review on pages 4 and 5: the Annual Report and also see Note 17.
The Review of our Business Chief Executive Officers review on pages 6 to 9: and the Review also includes information in respect of the Groups objectives, ofour Business on pages 48 to 61.
The Shire Annual Report also policies and processes for managing capital: its financial risk provides a description of the principal risks and uncertainties management objectives: details of its hedging activity: and its facing the Company and the Group as well as the Groups risk exposures to credit risk and liquidity risk.
Details of the Companys management objectives and policies that are in place to assist financial instruments are disclosed in Note 13 on page 183 to inmitigating the potential impact.
During the year the Company continued in its capacity as the The Companys funding requirements depend on a number of parent company for the Group in the management of its factors, including the timing and extent of its development subsidiaries.
programs: corporate, business and product acquisitions: the level of resources required for the expansion of certain manufacturing The Company is tax resident in the Republic of Ireland.
and marketing capabilities as the product base expands: increases Key performance indicators in accounts receivable and inventory which may arise with any The Companys key performance indicators are the same as the increase in product sales: competitive and technological Groups.
For details of the Groups key performance indicators see developments: the timing and cost of obtaining required regulatory page 16 in the Shire Annual Report.
approvals for new products: the timing and quantum of milestone payments on business combinations, in-licenses and collaborative Income Access Share arrangements projects: the timing and quantum of tax and dividend payments: In 2008 Shire put in place and continues to operate Income the timing and quantum of purchases by the Employee Benefit Access Share IAS arrangements enabling shareholders to Trust of Shire shares in the market to satisfy awards granted under choose whether they receive their dividends from a company tax Shires employee share plans: and the amount of cash generated resident in the Republic of Ireland or from a company tax resident from sales of Shires products and royalty receipts.
Further details in respect of the IAS arrangements can be found in Note 22 of the Shire Annual Report.
An important part of Shires business strategy is to protect its products and technologies through the use of patents, proprietary Results and dividends technologies and trademarks, to the extent available.
The Company A loss on ordinary activities before taxation of $91.5million was intends to defend its intellectual property and as a result may need recorded for the year ended December 31, 2015 year ended cash for funding the cost of litigation.
December 31, 2014: profit before taxation of $1,479.9million.
Thedecrease was primarily as a result of the break fee received of$1,635.4million following the termination of a cooperation agreement with AbbVie during 2014.
168 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information The Company finances its activities through cash generated from Auditor operating activities: credit facilities: private and public offerings of Each of the persons who is a Director at the date of approval of equity and debt securities: and the proceeds of asset or this report confirms that: investment disposals.
so far as the Director is aware, there is no relevant audit Shires balance sheet includes $135.5million of cash and cash information of which the Companys auditor is unaware: and equivalents at December 31, 2015. the Director has taken all the steps that he she ought to have taken as a Director in order to make himself herself aware of any Shire has a revolving credit facility of $2,100million which matures relevant audit information and to establish that the Companys in 2020, $750million of which was utilized as December 31, 2015. auditor is aware of that information.
The Directors have a reasonable expectation that the Company Deloitte LLP have expressed their willingness to continue in office and the Group has adequate resources to continue in operational as auditor and a resolution to reappoint them will be proposed at existence for the foreseeable future.
Accordingly the Directors the forthcoming Annual General Meeting.
continue to adopt the going concern basis of accounting in preparing the financial statements.
Further details regarding the Approved by the Board of Directors and signed on its behalf by: adoption of the going concern basis can be found in the accounting policies in the notes to the financial statements.
Directors The Directors who served during the year and up to the date of signing these financial statements are shown below: Dr Flemming Ornskov Bill Mordan Dominic Blakemore Company Secretary Olivier Bohuon appointed July 01, 2015 February 23, 2016 William Burns Dr Steven Gillis Dr David Ginsburg David Kappler Susan Kilsby Sara Mathew appointed September 01, 2015 Anne Minto OBE David Stout resigned April 28, 2015 Jeffrey Poulton appointed April 29, 2015 Payment of creditors The Company is non-trading and accordingly has no trade creditors.
Directors liability insurance and indemnification In the year under review, the Group maintained an insurance policy for its Directors and Officers in respect of liabilities arising out of any act, error or omission whilst acting in their capacity as Directors or Officers.
Qualifying third party indemnity provisions were also in place during the year under review for the benefit of Directors in relation to certain losses and liabilities which they may potentially incur to third-parties in the course of their duties.
Theseremain in force at the date of this report.
Subsequent events Shire provided funding for the acquisition of Dyax Corp. OnJanuary 20, 2016, Shire delivered a utilization request providingforthe draw down of an amount equal to $5.6 billion under the November 2015 Facilities Agreement in respect of the purchase price payable in respect of the acquisition of Dyax Corp.
In connection with the consummation of the Merger and for general corporate purposes, on January 20, 2016, Shire delivered a utilization request providing for the draw down of an amount equal to $100million under the RCF.
Shire will provide funding for the announced combination with Baxalta.
On January 11, 2016, Shire entered into an $18 billion bridge Facilities Agreement with certain financial institutions related to the announced combination with Baxalta.
As at February 23, 2016, the bridge Facilities Agreement was undrawn.
Shire Annual Report 2015 169 Directors responsibilities statement The Directors are responsible for preparing the Annual Report and Responsibility statement the financial statements in accordance with applicable law and We confirm that to the best of our knowledge: regulations.
the financial statements, prepared in accordance with United Company law requires the Directors to prepare financial statements Kingdom Generally Accepted Accounting Practice, including for each financial year.
Under that law the Directors have elected to FRS102 The Financial Reporting Standard applicable in the UK prepare the financial statements in accordance with United Kingdom and Republic of Ireland, give a true and fair view of the assets, Generally Accepted Accounting Practice United Kingdom Accounting liabilities, financial position and profit or loss of the company and Standards and applicable law, including FRS102 The Financial the undertakings included in the consolidation taken as a whole: Reporting Standard applicable in the UK and Republic of Ireland.
and Under company law the Directors must not approve the financial the annual report and financial statements, taken as a whole, statements unless they are satisfied that they give a true and fair arefair, balanced and understandable and provide the view of the state of affairs of the company and of the profit or information necessary for shareholders to assess the lossof the company for that period.
In preparing these financial companysperformance, business model and strategy.
statements, the Directors are requiredto: By order of the Board select suitable accounting policies and then apply them consistently: make judgments and accounting estimates that are reasonable and prudent: state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements: prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The Directors are responsible for keeping proper accounting Flemming Ornskov, MD, MPH records that are sufficient to show and explain the companys Director transactions and disclose with reasonable accuracy at any time February 23, 2016 the financial position of the company and enable them to ensure that the financial statements comply with the Companies Jersey Law 1991.
They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the Companys Jeffrey Poulton website.
Legislation in the United Kingdom governing the Director preparation and dissemination of financial statements may differ from legislation in other jurisdictions.
February 23, 2016 170 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information Independent auditors report to the members of Shire plc Opinion on the financial statements of Shire plc Going concern In our opinion the financial statements: We have reviewed the Directors statement regarding the appropriateness of the going concern basis of accounting contained give a true and fair view of the state of the Companys affairs as within the Accounting Policies section of the financial statements.
at December 31, 2015 and of its loss for the year then ended: We confirm that: have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including we have concluded that the Directors use of the going concern FRS 102 The Financial Reporting Standard applicable in the basis of accounting in the preparation of the financial statements UKand Republic of Ireland: and is appropriate: and have been prepared in accordance with the Companies Jersey we have not identified any material uncertainties that may cast Law 1991. significant doubt on the Companys ability to continue as a going concern.
The financial statements comprise the Statement of Comprehensive Income, Statement of Financial Position, However, because not all future events or conditions can be Statement of Changes in Equity, Statement of Cash Flows and the predicted, this statement is not a guarantee as to the companys related Notes A to P. The financial reporting framework that has ability to continue as a going concern.
been applied in their preparation is applicable law and United Independence Kingdom Accounting Standards United Kingdom Generally We are required to comply with the Financial Reporting Councils Accepted Accounting Practice.
Ethical Standards for Auditors and we confirm that we are independent of the Group and we have fulfilled our other ethical responsibilities in accordance with those standards.
We also confirm we have not provided any of the prohibited non-audit services referred to in those standards.
Our assessment of risks of material misstatement The assessed risks of material misstatement described below are those that had the greatest effect on our audit strategy, the allocation of resources in the audit and directing the efforts of the engagement team: Risk How the scope of our audit responded to the risk Investment in subsidiaries There is a risk related to the size of the Companys investments of We have challenged the Directors impairment analysis and have considered $16.7billion in Shire Pharmaceutical Holdings Ireland Limited and the valuation of the Companys subsidiaries against other indicators of value, ShireRegenerative Medicine Inc. which are disclosed in Note 10. such as the overall market capitalization of the Shire Group.
The risk related to complex tax judgments is not presented this year as we concluded on the most significant tax judgment, related to the tax treatment of the $1.6billion received from AbbVie Inc. was concluded in the prior year and there have been no developments in relation to the treatment.
These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, andwe do not provide a separate opinion on these matters.
Our application of materiality We define materiality as the magnitude of misstatement in the financial statements that makes it probable that the economic decisions ofa reasonably knowledgeable person would be changed or influenced.
We use materiality both in planning the scope of our audit work and in evaluating the results of our work.
We have reconsidered materiality in the current year, and have determined materiality for the Company to be $30million 2014: $69million.
This represents 0.2% 2014: 0.6% of the net assets of the Company.
We agreed with the Audit Committee that we would report to the Committee all audit differences in excess of $1.5 million 2014: $3million, as well as differences below that threshold that, in our view, warranted reporting on qualitative grounds.
We also report to the Audit Committee on disclosure matters that we identified when assessing the overall presentation of the financial statements.
An overview of the scope of our audit Our audit was scoped by obtaining an understanding of the entity and its environment, including internal control, and assessing the risks of material misstatement.
Audit work to respond to the risks of material misstatement was performed directly by the audit engagement team.
Matters on which we are required to report by exception Adequacy of explanations received and accounting records Under the Companies Jersey Law 1991 we are required to report to you if, in our opinion: we have not received all the information and explanations we require for our audit: or proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited byus: or the financial statements are not in agreement with the accounting records and returns.
We have nothing to report in respect of these matters.
Shire Annual Report 2015 171 Independent auditors report to the members of Shire plc continued Our duty to read other information in the Annual Report to the companys members those matters we are required to state Under International Standards on Auditing UK and Ireland, we are to them in an Auditors report and or those further matters we required to report to you if, in our opinion, information in the annual expressly agreed to report to them on in our engagement letter report is: and for no other purpose.
To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than materially inconsistent with the information in the audited the company and the companys members as a body, for our audit financial statements: or work, for this report, or for the opinions we have formed.
apparently materially incorrect based on, or materially Scope of the audit of the financial statements inconsistent with, our knowledge of the Company acquired in An audit involves obtaining evidence about the amounts and the course of performing our audit: or disclosures in the financial statements sufficient to give reasonable otherwise misleading.
assurance that the financial statements are free from material misstatement, whether caused by fraud or error.
This includes an In particular, we are required to consider whether we have assessment of: whether the accounting policies are appropriate to identified any inconsistencies between our knowledge acquired the Companys circumstances and have been consistently applied during the audit and the Directors statement that they consider and adequately disclosed: the reasonableness of significant the annual report is fair, balanced and understandable and accounting estimates made by the Directors: and the overall whether the annual report appropriately discloses those matters presentation of the financial statements.
In addition, we read all the that we communicated to the audit committee which we consider financial and non-financial information in the annual report to should have been disclosed.
We confirm that we have not identify material inconsistencies with the audited financial identified any such inconsistencies or misleading statements.
statements and to identify any information that is apparently Respective responsibilities of Directors and auditor materially incorrect based on, or materially inconsistent with, the As explained more fully in the Directors Responsibilities knowledge acquired by us in the course of performing the audit.
If Statement, the Directors are responsible for the preparation of the we become aware of any apparent material misstatements or financial statements and for being satisfied that they give a true inconsistencies we consider the implications for our report.
Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing UK and Ireland.
We also comply with International Standard on Quality Control 1 UK and Ireland.
Our audit methodology and tools aim to ensure that our quality control procedures are effective, understood and applied.
Our quality controls and systems include our dedicated professional standards review team and independent partner reviews.
This report is made solely to the companys members, as a body, James Bates in accordance with Article 113A of the Companies Jersey Law Senior Statutory Auditor 1991.
Our audit work has been undertaken so that we might state For and on behalf of Deloitte LLP Chartered Accountants and Recognized Auditors London February 23, 2016 172 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information Statement of comprehensive income for the year ended December 31, 2015 2015 2014 Notes $M $M Turnover Administrative expenses 28.6 112.6 Operating loss 28.6 112.6 Interest receivable 2 0.3 Interest payable and similar charges 3 63.2 42.9 Receipt of break fee 4 1,635.4 Loss profit on ordinary activities before taxation 5 91.5 1,479.9 Taxation 8 Loss profit on ordinary activities after taxation and profit for the year 91.5 1,479.9 Other comprehensive income Total comprehensive loss income for the year attributable to equity shareholders of the company 91.5 1,479.9 Shire Annual Report 2015 173 Statement of financial position for the year ended December 31, 2015 2015 2014 Notes $M $M Fixed assets Investments 10 16,704.8 13,039.0 Current assets Debtors 11 86.6 1,690.2 Current liabilities Creditors: amounts falling due within one year 12 4,715.6 2,671.9 Net current liabilities 4,629.0 981.7 Total assets less current liabilities 12,075.8 12,057.3 Net assets 12,075.8 12,057.3 Capital and reserves Called-up share capital 15 58.9 58.7 Share premium account 7,088.1 7,071.7 Share-based payments 608.2 512.4 Own shares held 15 260.5 275.6 Profit and loss account 4,581.1 4,690.1 Total equity 12,075.8 12,057.3 The financial statements on pages 173 to 177 were approved by the Board of Directors and authorized for issue on February 23, 2016 and are signed on its behalf by: Jeffrey Poulton Director 174 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information Statement of changes in equity for the year ended December 31, 2014 ShareOwn Profit Share Share based shares & loss capital premium payments held account Total Notes $M $M $M $M $M $M Balance at December 31, 2013 58.5 7,056.7 418.3 300.1 3,240.7 10,474.1 Changes on transition to FRS 102 22 Balance at January 1, 2014 58.5 7,056.7 418.3 300.1 3,240.7 10,474.1 Profit for the year and total comprehensive income 22A 1,479.9 1,479.9 Transactions with owners in their capacity asowners: Dividends 9 8.9 8.9 Issue of shares on options exercised 0.2 15.0 15.2 Transfer of Treasury Shares for new share issue 24.5 24.5 Share-based payments 2.9 2.9 Capital contribution relating to share basedpayments 94.1 94.1 Total transactions with owners in their capacity asowners 0.2 15.0 94.1 24.5 30.5 103.3 Balance at December 31, 2014 58.7 7,071.7 512.4 275.6 4,690.1 12,057.3 Shire Annual Report 2015 175 Statement of changes in equity for the year ended December 31, 2015 ShareOwn Profit Share Share based shares & loss capital premium payments held account Total Notes $M $M $M $M $M $M Balance at January 1, 2015 58.7 7,071.7 512.4 275.6 4,690.1 12,057.3 Loss for the year and total comprehensive income for the year 91.5 91.5 Transactions with owners in their capacity asowners: Dividends 9 6.8 6.8 Issue of shares on options exercised 0.2 16.4 16.6 Transfer of Treasury Shares for new share issue 15.1 15.1 Share-based payments 4.4 4.4 Capital contribution relating to share basedpayments 95.8 95.8 Total transactions with owners in their capacity asowners 0.2 16.4 95.8 15.1 17.5 110.0 Balance at December 31, 2015 58.9 7,088.1 608.2 260.5 4,581.1 12,075.8 176 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information Statement of cash flows for the year ended December 31, 2015 2015 2014 Notes $M $M Operating activities Cash used by generated from operations 16 81.3 1,545.8 Income taxes paid Net cash used by generated from operating activities 81.3 1,545.8 Investing activities Acquisition of investment in subsidiary 3,570.0 1,902.1 Decrease in investment in subsidiary 2.1 Net cash used in investing activities 3,570.0 1,900.0 Financing activities Proceeds from issuance of shares 16.6 15.2 Net proceeds of new external borrowings 650.0 850.0 Net proceeds from to intercompany borrowings 3,048.2 458.3 Interest paid 53.8 33.2 Facility arrangement fees paid 2.9 10.6 Dividends paid 9 6.8 8.9 Net cash from financing activities 3,651.3 354.2 Net movement in cash and cash equivalents Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year Shire Annual Report 2015 177 Accounting policies for the year ended December 31, 2015 General information Going concern Shire plc the Company is a public limited company incorporated The Groups balance sheet includes $135.5million of cash and in Jersey and domiciled in Ireland.
The address of the Companys registered office is 22 Grenville The Company has a revolving credit facility of $2,100million which Street, St Helier, JE4 8PX, Jersey.
matures in 2020, $750million of which was utilized as December 31, 2015.
The address of the Companys principal place of business is 5Riverwalk, Citywest Business Campus, Dublin 24, In connection with the acquisitions of NPS Pharma and Dyax and RepublicofIreland.
the proposed combination with Baxalta, Shire entered into a number of facility arrangements in the year to December 31, 2015 The Company is the ultimate parent of the Shire Group of and subsequently in 2016. companies and its principal activity is that of a holding company.
The Group has access to certain short-term uncommitted lines First time adoption of FRS 102 ofcredit which it utilizes from time to time to provide short-term These financial statements are the first financial statements of flexibility in cash management.
At December 31, 2015, these Shire plc prepared in accordance with Financial Reporting facilities were not utilized.
Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland FRS 102.
The financial statements The Directors have a reasonable expectation that the Company of Shire plc for the year ended December 31, 2014 were prepared has adequate resources to continue in operational existence for in accordance with previous UK GAAP.
Accordingly the Directors continue to adopt the going concern basis of accounting in preparing the report and Some of the FRS 102 recognition, measurement, presentation and financial statements.
disclosure requirements and accounting policy choices differ from previous UK GAAP.
Consequently, the Directors have amended Functional and presentational currencies certain accounting policies to comply with FRS 102.
For further The financial statements are presented in US Dollars which is also details refer to Note 22.
The Directors have also taken advantage the functional currency of the Company.
of certain exemptions from the requirements of FRS 102 permitted Foreign currencies by FRS 102 Section 35 Transition to this FRS.
Transactions in currencies other than the functional currency Comparative figures have been restated to reflect the adjustments foreign currencies are initially recorded at the exchange rate ruling made, except to the extent that the Directors have taken advantage on the date of the transaction.
of exemptions to retrospective application of FRS 102 permitted Monetary assets and liabilities denominated in foreign currencies byFRS 102 Section 35 Transition to this FRS.
Adjustments are are translated at the rate of exchange ruling at the reporting date.
recognized directly in retained earnings at the transition date.
Non-monetary assets and liabilities denominated in foreign Basis of accounting currencies are translated at the rate ruling at the date of the These financial statements have been prepared in accordance transaction or, if the asset or liability is measured at fair value, with FRS 102 The Financial Reporting Standard applicable in therate when that fair value was determined.
theUK and Republic of Ireland FRS 102 and the requirements All translation differences are taken to profit or loss, except to of the Companies Jersey Law 1991, and under the historical theextent that they relate to gains or losses on non-monetary costconvention.
items recognized in other comprehensive income, when the Monetary amounts in these financial statements are rounded to related translation gain or loss is also recognized in other the nearest whole $100,000, except where otherwise indicated.
Consolidated financial statements Other income Consolidated accounts prepared in conformity with accounting Interest income principles generally accepted in the United States of America Interest income is accrued on a time-apportioned basis, by reference USGAAP, in which the financial results and cash flow to the principal outstanding at the effective interest rate.
statement of the Company and its subsidiaries are included, can Dividend income be found in the Shire Annual Report.
Consequently, these financial Dividend income from investments in subsidiaries is recognized statements present the financial position and financial when the Companys right to receive payment is established.
performance of the Company as a separate entity.
Borrowing costs These financial statements have been prepared in accordance Finance costs relating to debt issued are recorded as a deferred with the Companys accounting policies described below, which charge and amortized to the statements of income over the period have been applied consistently throughout the current and to the earliest redemption date of the debt, using the effective preceding year and have been approved by the Board.
On extinguishment of the related debt, any The financial statements of the Company are consolidated in the unamortized deferred financing costs are written off and charged financial statements of Shire plc.
The consolidated financial to interest expense in the consolidated statements of income.
statements of Shire plc are available from their registered office at 22 Grenville Street, St Helier, JE4 8PX, Jersey or on their website, www.
178 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information Fixed asset investments Financial instruments Interests in subsidiaries, associates and jointly controlled entities The Company has elected to apply the provisions of Section 11 are initially measured at cost and subsequently measured at cost Basic Financial Instruments and Section 12 Other Financial less any accumulated impairment losses.
Instruments Issues of FRS 102, in full, to all of its financial instruments.
Interests in subsidiaries, associates and jointly controlled entities are assessed for impairment at each reporting date.
Any impairment Financial assets and financial liabilities are recognized when the losses or reversals of impairment losses are recognized immediately Company becomes a party to the contractual provisions of the in profit or loss.
instrument, and are offset only when the Company currently has alegally enforceable right to set off the recognized amounts and Taxation intends either to settle on a net basis, or to realize the asset and The tax expense represents the sum of the current tax expense settle the liability simultaneously.
Current tax assets are recognized whentax paid exceeds the tax payable.
Financial assets Trade debtors Current tax is based on taxable profit for the year.
Taxable profit Trade debtors which are receivable within one year and which do differs from total comprehensive income because it excludes items not constitute a financing transaction are initially measured at the of income or expense that are taxable or deductible in other transaction price.
Trade debtors are subsequently measured at periods.
Current tax assets and liabilities are measured using amortized cost, being the transaction price less any amounts taxrates that have been enacted or substantively enacted by the settled and any impairment losses.
Where the arrangement with a trade debtor constitutes a financing Deferred tax is calculated at the tax rates that are expected to transaction, the debtor is initially and subsequently measured at apply to the period when the asset is realized or the liability is the present value of future payments discounted at a market rate settled based on tax rates that have been enacted or substantively of interest for a similar debt instrument.
enacted by the reporting date.
Deferred tax is not discounted.
A provision for impairment of trade debtors is established when Deferred tax liabilities are recognized in respect of all timing there is objective evidence that the amounts due will not be differences that exist at the reporting date.
Timing differences collected according to the original terms of the contract.
aredifferences between taxable profits and total comprehensive Impairment losses are recognized in profit or loss for the excess of income that arise from the inclusion of income and expenses in the carrying value of the trade debtor over the present value of the taxassessments in different periods from their recognition in the future cash flows discounted using the original effective interest financial statements.
Deferred tax assets are recognized only to rate.
Subsequent reversals of an impairment loss that objectively the extent that it is probable that they will be recovered by the relate to an event occurring after the impairment loss was reversal of deferred tax liabilities or other future taxable profits.
recognized, are recognized immediately in profit or loss.
Deferred tax is recognized on income or expenses from Financial liabilities and equity subsidiaries, associates, branches and interests in jointly Financial instruments are classified as liabilities and equity controlled entities, that will be assessed to or allow for tax in a instruments according to the substance of the contractual future period except where the Company is able to control the arrangements entered into.
An equity instrument is any contract reversal of the timing difference and it is probable that the timing that evidences a residual interest in the assets of the Company difference will not reverse in the foreseeable future.
after deducting all of its liabilities.
Current and deferred tax is charged or credited in profit or loss, Equity instruments except when it relates to items charged or credited to other Financial instruments classified as equity instruments are recorded comprehensive income or equity, when the tax follows the at the fair value of the cash or other resources received or transaction or event it relates to and is also charged or credited receivable, net of direct costs of issuing the equity instruments.
toother comprehensive income, or equity.
Own shares Current tax assets and current tax liabilities and deferred tax The fair value of consideration given for shares repurchased by assets and deferred tax liabilities are offset, if and only if, there is theCompany is deducted from equity.
alegally enforceable right to set off the amounts and the entity intends either to settle on a net basis or to realize the asset and Trade creditors settle the liability simultaneously.
Trade creditors payable within one year that do not constitute a financing transaction are initially measured at the transaction price Employee benefits and subsequently measured at amortized cost, being the The costs of short-term employee benefits are recognized as a transaction price less any amounts settled.
Where the arrangement with a trade creditor constitutes a Retirement benefits financing transaction, the creditor is initially and subsequently The Company contributes to personal defined contribution measured at the present value of future payments discounted pension plans of employees.
Contributions are charged to the atamarket rate of interest for a similar instrument.
profit and loss account as they become payable.
Differences between contributions payable in the year and contributions actually paid are shown as either accruals or prepayments in thebalance sheet.
Shire Annual Report 2015 179 Accounting policies for the year ended December 31, 2015 continued Borrowings Borrowings are initially recognized at the transaction price, including transaction costs, and subsequently measured at amortized cost using the effective interest method.
Interest expense is recognized on the basis of the effective interest method and is included in interest payable and other similar charges.
Commitments to receive a loan are measured at cost less impairment.
Derecognition of financial assets and liabilities A financial asset is derecognized only when the contractual rights to cash flows expire or are settled, or substantially all the risks and rewards of ownership are transferred to another party, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.
A financial liability or part thereof is derecognized when the obligation specified in the contract is discharged, canceled or expires.
Share based payments The Company grants share options equity-settled share-based payments to certain employees.
Equity-settled share-based payments are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted.
Options and performance share awards granted without market conditions are valued using the Black-Scholes optionpricing model.
Options and performance share awards granted with market conditions are valued using a binomial model.
The Company participates in a share-based payment arrangement granted to its employees and employees of its subsidiaries.
TheCompany has elected to recognize and measure its sharebased payment expense on the basis of a reasonable allocation ofthe expense for the Group.
The cost for awards granted to the Companys subsidiaries employees represents additional capital contributions by the Company in its subsidiaries.
An additional investment in subsidiaries has been recorded in respect of those awards granted to the Companys subsidiaries employees, with a corresponding increase in the Companys shareholders equity.
The additional capital contribution is based on the fair value at thegrant date of the awards issued.
This accounting treatment applies as the parent has granted the share option rather than being subsidiary granting an option in the parents equity.
Dividends Dividends are recognized as liabilities once they are no longer atthe discretion of the Company.
180 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information Notes to the financial statements for the year ended December 31, 2015 1 Critical accounting estimates and areas of judgment 5 Loss profit on ordinary activities before taxation Estimates and judgments are continually evaluated and are based Loss Profit on ordinary activities is stated after charging crediting : on historical experience and other factors, including expectations 2015 2014 of future events that are believed to be reasonable under the $M $M circumstances.
Share based payments 4.4 2.9 Critical accounting estimates and areas of judgment Foreign exchange gains losses 0.3 0.1 The Company makes estimates and assumptions concerning the future.
The resulting accounting estimates and assumptions will, Fees payable to Deloitte LLP and its associates in respect of both by definition, seldom equal the related actual results.
The estimates audit and non-audit services are borne by a subsidiary undertaking.
and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within 6 Segmental reporting the next financial year are discussed below: The Directors consider that the Company, in its capacity as a holding company, operates as one operating segment.
Therefore, The only critical accounting judgment which the Directors believe there is no additional disclosure to make as required by FRS 102 are relevant to these financial statements are those relating to the paragraph 1.5. treatment of share based payments in the company.
Please see the accounting policy above for treatment of the share based 7 Employees payments in these financial statements.
The average monthly number of persons including Directors employed by the Company during the year was: 2 Interest receivable and similar income 2015 2014 2015 2014 $M $M $M $M Interest receivable on deposit to Directors 1 1 Groupundertakings 0.3 There were no staff other than the Directors.
3 Interest payable and similar charges Directors In respect of the Directors of Shire plc: 2015 2014 $M $M 2015 2014 Interest arising on bank loans 29.1 27.1 $M $M Interest arising on loans from Wages and salaries 2.1 3.5 Groupundertakings 34.1 15.8 Social security costs 0.1 0.2 63.2 42.9 Defined contribution pension costs 0.1 0.1 Employee share schemes 4.4 2.9 4 Receipt of break fee Directors fees 2.6 2.2 2015 2014 9.3 8.9 $M $M AbbVie break fee 1,635.4 2015 2014 On July 18, 2014 the Boards of AbbVie and Shire announced that $M $M they had agreed the terms of a recommended combination of The number of Directors to whom Shire with AbbVie, subject to a number of conditions including retirementbenefits are accruing under approval by shareholders and regulators.
On the same date Shire money purchase schemes was: 2 2 and AbbVie entered into a co-operation agreement in connection The number of Directors who exercised with the recommended combination.
On October 16, 2014 the share options during the year was: 2 1 Board of AbbVie confirmed that it had withdrawn its recommendation of its offer for Shire as a result of the anticipated The number of Directors who received impact of the US Treasury Notice on the benefits that AbbVie shares under long term incentive expected from its offer.
As AbbVies offer was conditional on the schemeswas: 2 2 approval of its stockholders, and given their Boards decision to Directors emoluments disclosed above include the following change its recommendation and to advise AbbVies stockholders payments made to the highest paid Director: to vote against the offer, there was no realistic prospect of satisfying this condition.
Accordingly, Shires Board agreed with 2015 2014 AbbVie to terminate the cooperation agreement on October 20, $M $M 2014.
The Company entered into a termination agreement with Remuneration 1.6 1.4 AbbVie, pursuant to which AbbVie paid the break fee due under the cooperation agreement of approximately $1,635million.
Company contributions to money purchase pension schemes 0.1 0.1 TheCompany has obtained advice that the break fee should not be taxable in Ireland.
The Company continues to consider that no Share based payments 4.1 2.8 taxliability should arise and did not recognize a tax charge in the 5.8 4.3 income statement in 2014.
The relevant tax return was submitted on September 23, 2015.
Shire Annual Report 2015 181 Notes to the financial statements for the year ended December 31, 2015 continued 8 Taxation 10 Fixed asset investments There was $nil corporation tax charged for the year ended Subsidiary December 31, 2015 2014 $nil.
undertakings $M Factors affecting the tax charge for the year.
Cost The tax assessed for the year is lower than the standard rate of As at January 1, 2015 13,039.0 corporation tax in Ireland of 25% 2014: 25%.
The differences are Additions 3,570.0 explained below: Capital contribution relating to share based payments 95.8 2015 2014 As at December 31, 2015 16,704.8 $M $M Net book value Company losses profit on ordinary As at December 31, 2015 16,704.8 activitiesbefore tax 91.5 1,479.9 As at December 31, 2014 13,039.0 Company profit on ordinary activities multiplied by the standard rate of On February 25, 2015 the Company purchased 714,000,000 corporation tax of 25% 2014: 25% : 22.9 370.0 further ordinary shares in Shire Pharmaceuticals Holdings Ireland Effects of: Limited, for consideration of $3,570.0million.
Expenses not deductible for tax purposes 17.1 31.6 Subsidiaries Income not subject to taxation 409.0 The Company owned directly 100% of the issued ordinary share Group relief surrendered 5.8 5.4 capital unless stated otherwise below of the following companies Unrecognized movements in deferred tax 2.0 at December 31, 2015: Principal Country of Company activities incorporation Holding The Company had an unrecognized deferred tax asset of $21.8million 2014: $22.4million in respect of short term timing Shire Pharmaceutical Holding Republic differences and losses as at December 31, 2015.
Holdings Ireland Limited company of Ireland 100% Shire Regenerative Holding United States 9 Dividends Medicine LLC company of America 100% 2015 2014 Holding United States $M $M BearTracks Inc. company of America 100% Second interim dividend 17.09 cents Details of the Companys indirect subsidiaries can be found in 10.21 pence per Ordinary share, Note 31 of the Shire Annual Report in the consolidated accounts equivalent to 50.79 cents per ADS, for the year ending December 31, 2015. paidin April 2014 100.0 First interim dividend 3.64 cents 11 Debtors 2.24pence per Ordinary share, 2015 2014 equivalent to 11.49 cents per ADS, $M $M paidin October 2014 21.6 Amounts due from Group undertakings 80.7 1,679.6 Second interim dividend 19.09 cents Other debtors 5.9 10.6 12.51 pence per Ordinary share, equivalent to 57.27 cents per ADS, Prepayments and accrued income paidin April 2015 110.2 86.6 1,690.2 First interim dividend 4.21 cents 2.69pence per Ordinary share, The amounts due from Group undertakings are primarily US dollar equivalent to 12.63 cents per ADS, denominated and non-interest bearing.
At December 31, 2014 an paidin October 2015 24.2 amount of $1,637.1million bore interest at floating rates of interest.
The remaining balance is non-interest bearing.
All amounts due 134.4 121.6 from Group undertakings are repayable on demand.
Of the above amounts, the Company paid dividends amounting to 12 Creditors: amounts falling due within one year $6.8million in the year 2014: $8.9million.
In accordance with IAS arrangements, Shire Biopharmaceuticals Holdings paid dividends 2015 2014 totaling $127.6million 2014: $112.7million to those shareholders $M $M who chose to receive their dividends from a company tax resident Bank loan Note 14 1,500.0 850.0 in the UK.
Amounts owed to Group undertakings 3,205.3 1,772.2 The Board has resolved to pay a second interim dividend of 22.16 Accrued interest 0.6 0.2 cents 15.56 pence per Ordinary Share equivalent to 66.48 cents Other creditors 9.7 49.5 per ADS for the six months to December 31, 2015.
4,715.6 2,671.9 The amounts due to Group undertakings are primarily unsecured, US dollar denominated, repayable on demand and bear interest at floating rates of interest.
182 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information 13 Financial instruments 15 Share capital and reserves The carrying amount of the Companys financial instruments at Share capital December 31 were: 2015 2015 2014 2014 No $M No $M 2015 2014 Authorized $M $M Ordinary shares of Financial assets 5peach 1,000,000,000 99.1 1,000,000,000 99.1 Debt instruments measured at Subscriber Ordinary amortizedcost shares of 1 each 2 2 Amounts due from Group undertakings 80.7 1,679.6 99.1 99.1 Other debtors 5.9 10.6 Allotted, issued and 86.6 1,690.2 fullypaid Ordinary shares of 5peach 601,075,964 58.9 599,057,502 58.7 2015 2014 Subscriber Ordinary $M $M shares of 1 each 2 2 Financial liabilities 58.9 58.7 Measured at amortized cost Ordinary share rights Bank loans 1,500.0 850.0 The Companys Ordinary shares, which carry no right to fixed Amounts owed to Group undertakings 3,205.3 1,772.2 income, each carry the right to one vote at general meetings of Accrued interest 0.6 0.2 theCompany.
Other creditors 9.7 49.5 As at December 31, 2015, the Companys issued ordinary share 4,715.6 2,671.9 capital comprised 592,548,261 Ordinary shares of 5p each with voting rights and a further 8,527,703 Ordinary shares held in 14 Borrowings treasury.
Therefore the total number of voting rights in the 2015 2014 Company at December 31, 2015 was 592,548,261.
$M $M Share issues Bank loan 1,500.0 850.0 During the year 2,018,462 2014: 1,515,158 Ordinary shares of 5peach were issued as part of the Shire Groups share based During the year, funds from the 2014 Revolving Credit Facility, payment scheme.
There were no other share issues during the which matures in 2020, were utilized to partially finance the current or comparative year.
acquisition of NPS Pharmaceuticals Inc. On January 11, 2015 theGroup also entered into a $850million term loan facility Share option scheme agreement, which originally matured on January 10, 2016 and Further details in respect of the Ordinary shares reserved for issue wasextended to July 11, 2016, which was also used to fund the under the Companys share option plan can be found in Note 29 acquisition.
The loans under these facilities are denominated in ofthe Shire Annual Report.
USDollars and bear interest at a floating rate of interest.
Reserves At December 31, 2015 $750million of the Revolving Credit Facility Share premium and $750million of the 2015 Facility Agreement was utilized.
Consideration received for shares issued above their nominal value net of transaction costs.
Purchase of own shares The treasury shares reserve represents the cost of shares in the Company purchased in the market and held by the Company for the purpose of returning funds to shareholders.
The number of Ordinary shares of 5p each held by the Company as at December 31, 2015 was 8,527,703 with a purchase value of $260.5million 2014: 9,019,832 with a purchase value of $275.6million including transaction costs.
Share based payment reserve The cumulative share-based payment expense.
Retained earnings Cumulative profit and loss net of distributions to owners.
Shire Annual Report 2015 183 Notes to the financial statements for the year ended December 31, 2015 continued 16 Notes to the statement of cash flows The RCF includes customary representations and warranties, Reconciliation of profit after tax to net cash generated covenants and events of default, including requirements that fromoperations Shires i ratio of Net Debt to EBITDA in respect of the most recently-ended 12-month relevant period each as defined in the 2015 2014 RCF must not, at any time, exceed 3.5:1 except that, following $M $M anacquisition fulfilling certain criteria, Shire may on a once only basis elect to increase this ratio to a 5.5:1 for the relevant period Loss profit on ordinary activities in which the acquisition was completed b 5.0:1 in respect of the aftertaxation 91.5 1,479.9 firstrelevant period following the relevant period in which the Adjustments for: acquisition was completed and c 4.5:1 in respect of the second Share-based payment expense 4.4 2.9 relevant period following the relevant period in which the Interest payable 63.2 42.9 acquisition was completed, and ii ratio of EBITDA to Net Interest Interest receivable 0.3 for the most recently-ended 12-month relevant period each as Operating cash flows before movements defined in the RCF must not be less than 4.0:1. inworking capital 24.2 1,525.7 The RCF restricts, subject to certain exceptions, Shires ability Increase in other debtors 38.8 11.9 toincur additional financial indebtedness, grant security over its Decrease increase in other creditors 18.3 32.0 assets or provide loans grant credit.
Further, any lender may Cash used by generated from operations 81.3 1,545.8 require mandatory prepayment of its participation if there is a change of control of Shire, subject to certain exceptions for schemes of arrangement and analogous schemes.
17 Capital commitments and other contractual obligations Revolving Credit Facilities Agreement Events of default under the RCF include, subject to customary On December 12, 2014, Shire entered into a $2,100million grace periods and materiality thresholds: i non-payment of any revolving credit facilities agreement the RCF with a number of amounts due under the finance documents as defined in the financial institutions, for which Abbey National Treasury Services RCF, ii failure to satisfy any financial covenants, iii material PLC trading as Santander Global Banking and Markets, Bank of misrepresentation in any of the finance documents, iv failure to America Merrill Lynch International Limited, Barclays Bank PLC, pay, or certain other defaults, under other financial indebtedness, Citigroup Global Markets Limited, Lloyds Bank PLC, The Royal v certain insolvency events or proceedings, vi material adverse Bank of Scotland PLC and Sumitomo Mitsui Banking Corporation changes in the business, operations, assets or financial condition acted as mandated lead arrangers and bookrunners and DNB of Shire as a whole, vii if it becomes unlawful for Shire or any Bank ASA, The Bank of Tokyo-Mitsubishi UFJ, Ltd. Credit Suisse successor parent company or any of their respective subsidiaries AG, London Branch, Deutsche Bank Luxembourg S. A. Goldman that are parties to the RCF to perform their obligations thereunder Sachs Bank USA, Mizuho Bank, Ltd. and Morgan Stanley Bank or viii if Shire or any successor parent company or any International Limited acted as arrangers.
Shire is an original subsidiary thereof which is a party to the RCF repudiates such borrower and original guarantor under the RCF.
Shire has agreed agreement or other finance document, among others.
to act as guarantor for any of its subsidiaries that become additional borrowers under the RCF.
As at December 31, 2015 January 2016 Facilities Agreement theCompany utilized $750million of the RCF.
On January 11, 2016, Shire as original guarantor and original borrower, entered into an $18.0 billion bridge facilities agreement The RCF, which terminates on December 12, 2020, may be with, among others, Barclays Bank PLC Barclays, and Morgan applied towards financing the general corporate purposes of Shire.
Stanley Bank International Limited, acting as mandated lead The RCF incorporates a $250million US dollar and euro swingline arrangers and bookrunners the January 2016 Facilities Agreement.
facility operating as a sub-limit thereof.
The January 2016 Facilities Agreement comprises two credit Interest on any loans made under the RCF is payable on the last facilities: i a $13.0 billion term loan facility which, subject to a one year extension option exercisable at Shires option, matures on day of each interest period, which may be one week or one, two, three or six months at the election of Shire, or as otherwise agreed January 11, 2017 January 2016 Facility A and ii a $5.0 billion revolving loan facility which, subject to a one year extension with the lenders.
The interest rate for the RCF is: LIBOR or, in relation to any revolving loan in euro, EURIBOR : plus 0.30% per annum optionexercisable at Shires option, matures on January 11, 2017 January 2016 Facility B. Shire has agreed to act as guarantor for subject to change depending upon i the prevailing ratio of Net Debt to EBITDA each as defined in the RCF in respect of the most recently any of its subsidiaries that become additional borrowers under the January 2016 Facilities Agreement.
As of February 23, 2016, the completed financial year or financial half year and ii the occurrence and continuation of an event of default in respect of the financial January 2016 Facilities Agreement was undrawn.
covenants or the failure to provide a compliance certificate.
January 2016 Facility A may be used to finance the cash consideration payable in respect of the proposed combination with Shire shall also pay i a commitment fee equal to 35% of the Baxalta and certain costs related to the proposed combination.
applicable margin on available commitments under the RCF for January 2016 Facility B may be used to finance the redemption of theavailability period applicable thereto and ii a utilization fee all or part of Baxaltas senior notes upon completion of the equal to a 0.10% per year of the aggregate of all outstanding proposed combination.
loans up to an aggregate base currency amount equal to $700million, b 0.15% per year of the amount by which the aggregate base currency amount of all outstanding loans exceeds $700million but is equal to or less than $1,400million and c 0.30% per year of the amount by which the aggregate base currency amount of all outstanding loans exceeds $1,400million.
184 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information Interest on any loans made under the January 2016 Facilities November 2015 Facilities Agreement Agreement will be payable on the last day of each interest period, On November 2, 2015, Shire as original guarantor and original which may be one week or one, two, three or six months, or as borrower entered into a $5.6 billion facilities agreement with, otherwise agreed with the lenders.
The interest rate applicable to among others, Morgan Stanley Bank International Limited and the January 2016 Facilities Agreement is LIBOR plus 1.25 percent Deutsche Bank AG, London Branch acting as mandated lead per annum, increasing by: i 0.25 percent per annum on July 11, arrangers and bookrunners the November 2015 Facilities 2016 and on each subsequent date falling at three month intervals Agreement.
The November 2015 Facilities Agreement comprises thereafter until and excluding April 11, 2017 and ii 0.50 percent three credit facilities: i a $1.0 billion term loan facility which, per annum on April 11, 2017 and on each subsequent date falling subject to a one year extension option exercisable at Shires at three month intervals thereafter.
option, matures on November 2, 2016 November 2015 Facility A, ii a $2.2 billion amortizing term loan facility which matures Shire shall also pay a commitment fee on the available but onNovember 2, 2017 November 2015 Facility B and unutilized commitments under the January 2016 Facilities iii a$2.4billion amortizing term loan facility which matures Agreement for the availability period applicable to each facility.
onNovember 2, 2018 November 2015 Facility C. With effect from first utilization, the commitment fee rate will be 35percent of the applicable margin.
Before first utilization, the As of December 31, 2015, the November 2015 Facilities commitment fee rate shall be increased in stages from 10 percent Agreement was undrawn.
In January 2016 the November 2015 to 35 percent of the applicable margin over the period to May 11, 2016.
Facilities Agreement was utilized in full to finance the purchase price payable in respect of Shires acquisition of Dyax and certain The January 2016 Facilities Agreement includes customary costs related to the acquisition.
representations and warranties, covenants and events of default, including requirements that Shires i ratio of Net Debt to EBITDA Interest on any loans made under the November 2015 Facilities in respect of the most recently ended 12-month relevant period, Agreement is payable on the last day of each interest period, each as defined in the January 2016 Facilities Agreement, which may be one week or one, two, three or six months, or as mustnot, at any time, exceed 3.5:1, except that following the otherwise agreed with the lenders.
The interest rate applicable is combination with Baxalta, or any other acquisition fulfilling certain LIBOR plus, in the case of November 2015 Facility A, 0.55% per criteria, Shire may elect on a once only basis to increase this ratio annum, in the case of November 2015 Facility B, 0.65% per annum to a 5.5:1 for the relevant period in which the acquisition was and, in the case of November 2015 Facility C, 0.75% per annum, in completed, b 5.0:1 in respect of the first relevant period following each case until delivery of the first compliance certificate required the relevant period in which the acquisition was completed and to be delivered after the date of the November 2015 Facilities c 4.5:1 in respect of the second relevant period following the Agreement and is subject to change thereafter depending on i relevant period in which the acquisition was completed, and the prevailing ratio of Net Debt to EBITDA each as defined in the ii ratio of EBITDA to Net Interest, for the most recently ended November 2015 Facilities Agreement in respect of the most 12-month relevant period each as defined in the January 2016 recently completed financial year or financial half year and ii the Facilities Agreement must not be less than 4.0:1. occurrence and continuation of an event of default in respect of the financial covenants or failure to provide a compliance certificate.
The January 2016 Facilities Agreement restricts, subject to certainexceptions, Shires ability to incur additional financial The November 2015 Facilities Agreement includes customary indebtedness, grant security over its assets or provide loans grant representations and warranties, covenants and events of default, credit.
Further, any lender may require mandatory prepayment of including requirements that Shires i ratio of Net Debt to EBITDA its participation if there is a change of control of Shire, subject to in respect of the most recently ended 12-month relevant period certain exceptions for schemes of arrangement and analogous each as defined in the November 2015 Facilities Agreement, must schemes.
In addition, in certain circumstances and subject to not, at any time, exceed 3.5:1, except that following an acquisition certain broad exceptions, the net cash proceeds of disposals fulfilling certain criteria, Shire may elect on a once only basis to andcertain issues, loans, sales or offerings of debt securities increase this ratio to a 5.5:1 for the relevant period in which the byany member of Shires Group must be applied in cancelation acquisition was completed, b 5.0:1 in respect of the first relevant oftheavailable commitments under the January 2016 Facilities period following the relevant period in which the acquisition was Agreement and, if applicable, mandatory prepayment of any completed and c 4.5:1 in respect of the second relevant period loansmade under the January 2016 Facilities Agreement.
following the relevant period in which the acquisition was completed, and ii the ratio of EBITDA to Net Interest in respect of the most Events of default under the January 2016 Facilities Agreement recently ended 12-month relevant period each as defined in the include, subject to customary grace periods and materiality November 2015 Facilities Agreement, must not be less than 4.0:1. thresholds: i non-payment of any amounts due under the finance documents as defined in the January 2016 Facilities Agreement, ii failure to satisfy any financial covenants, iii material misrepresentation in any of the Finance Documents, iv failure to pay, or certain other defaults, under other financial indebtedness, v certain insolvency events or proceedings, vi material adverse changes in the business, operations, assets or financial condition of Shire as a whole, vii if it becomes unlawful for Shire or any successor parent company or any of their respective subsidiaries that are parties to the January 2016 Facilities Agreement to perform their obligations thereunder or viii if Shire or any successor parent company or any subsidiary thereof which is aparty to the January 2016 Facilities Agreement repudiates the January 2016 Facilities Agreement or any other finance document, among others.
Shire Annual Report 2015 185 Notes to the financial statements for the year ended December 31, 2015 continued 17 Capital commitments and other contractual obligations 18 Retirement benefits continued The Company operates a defined contribution pension scheme for The November 2015 Facilities Agreement restricts, subject to all qualifying employees in the United Kingdom.
The assets of the certain exceptions, Shires ability to incur additional financial scheme are held separately from those of the Company in an indebtedness, grant security over its assets or provide loans grant independently administered fund.
The contributions payable by the credit.
Further, any lender may require mandatory prepayment of Company charged to profit or loss amounted to $0.1million 2014: its participation if there is a change of control of Shire, subject to $0.1million.
Contributions totaling $nil 2014: $nil were payable to certain exceptions for schemes of arrangement and analogous the fund at the year end and are included in creditors.
19 Share based payments Events of default under the November 2015 Facilities Agreement Group share based payment plans include, subject to customary grace periods and materiality The Company participates in Group share-based payment plans, thresholds: i non-payment of any amounts due under finance and recognizes and measures its share-based payment expense documents as defined in the November 2015 Facilities on the basis of a reasonable allocation of the expense recognized Agreement, ii failure to satisfy any financial covenants, iii for the Group in accordance with paragraph 26.16 of FRS 102. material misrepresentation in any of the finance documents, iv Theallocation is based on the number of employees benefiting from failure to pay, or certain other defaults, under other financial the share-based payment plan employed by each Group entity.
indebtedness, v certain insolvency events or proceedings, vi Certain employees are contractually employed by other Group material adverse changes in the business, operations, assets or entities with elements of their payroll costs, including the share financial condition of Shire as a whole, vii if it becomes unlawful based payment charge relating to those employees, recharged to for Shire or any successor parent company or any of their Shire plc on the basis of the fair value of the work performed.
respective subsidiaries that are parties to the November 2015 Share options relating to those employees are not included in the Facilities Agreement to perform their obligations thereunder or viii disclosures given below relating to each of the schemes currently if Shire or any successor parent company or any subsidiary of in use.
thereof which is a party to the November 2015 Facilities Agreement repudiates the November 2015 Facilities Agreement or Equity settled share option plan LTIP and PSP Part A any other finance document, among others.
Equity-settled SARs granted under the LTIP and PSP Part A areexercisable subject to service and, for grants to Executive January 2015 Facility Agreement Directors only, performance criteria.
On January 11, 2015, Shire entered into an $850million term facility agreement with, among others, Citigroup Global Markets In respect of any award made to Executive Directors under the Limited acting as mandated lead arranger and bookrunner the LTIP, performance criteria are based on product sales and Non January 2015 Facility Agreement with an original maturity date of GAAP EBITDA targets, with a Non GAAP Adjusted ROIC underpin.
The maturity date was subsequently extended In respect of any award made to Executive Directors under the to July 11, 2016 in line with the provisions within the January 2015 PSP Part A, performance criteria are based on growth in Non Facility Agreement allowing the maturity date to be extended GAAP Adjusted ROIC and Non GAAP EBITDA.
These performance twice, at Shires option, by six months on each occasion.
measures are an important measure of the Companys ability to meet the strategic objective to grow value for all of its stakeholders.
The January 2015 Facility Agreement was available to finance the purchase price payable in respect of Shires acquisition of NPS Awards granted to employees below Executive Director level are Pharma including certain related costs.
On September 28, 2015 not subject to performance conditions and are only subject to the Company reduced the January 2015 Facility Agreement by service conditions.
As at December 31, 2015 the January 2015 Facility Once awards have vested, participants will have until the seventh Agreement, was fully utilized in the amount of $750million.
anniversary of the date of grant to exercise their awards.
InJanuary 2016 and at various points thereafter, the Company canceled parts of the January 2015 Facility Agreement.
On 2015 2015 2014 2014 February 22, 2016, the Company repaid in full the remaining Options WAEP Options WAEP balance of $100 million.
No $ No $ 2013 Facilities Agreement Outstanding at On November 11, 2013, Shire entered into a $2,600million facilities January 1, 2015 339,949 29.32 agreement with, among others, Morgan Stanley Bank International Granted during the year Limited acting as mandated lead arranger and bookrunner the Forfeited during the year 94,346 21.27 2013 Facilities Agreement.
The 2013 Facilities Agreement Exercised during the year 245,603 32.42 comprised two credit facilities: i a $1,750million term loan facility Expired during the year and ii an $850million term loan facility.
Outstanding at On December 13, 2013 and at various points thereafter, the December 31, 2015 Company canceled parts of the 2013 Facilities Agreement.
On Exercisable at September 28, 2015 the Company repaid in full the remaining December 31, 2015 134,814 31.47 balance of $350million under the 2013 Facilities Agreement.
Equity settled share option plan Shire Sharesave Scheme Share options granted under the Sharesave Plans are granted with an exercise price equal to 80% and 75% of the mid-market price on the day before invitations are issued to UK and Ireland employees, respectively.
Employees may enter into three or five year savings contracts.
186 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information 20 Related party transactions 2015 2015 2014 2014 The Company has taken advantage of the exemption in Options WAEP Options WAEP Section33of FRS 102 to disclose transactions with wholly No $ No $ ownedGroup companies.
Outstanding at January 1, 2015 467 19.24 The Directors consider that they are the only key management Granted during the year personnel of the company and details in respect of their remuneration is given in Note 7 to these financial statements.
Forfeited during the year 467 19.24 Exercised during the year 21 Post balance sheet events Expired during the year Shire provided funding for the acquisition of Dyax Corp.
Outstanding at OnJanuary 20, 2016, Shire delivered a utilization request December 31, 2015 providingforthe draw down of an amount equal to $5.6 billion under the November 2015 Facilities Agreement in respect of the Exercisable at purchase price payable in respect of the acquisition of Dyax Corp. December 31, 2015 In connection with the consummation of the Merger and for Equity settled share option plan LTIP and PSP Part B general corporate purposes, on January 20, 2016, Shire delivered PSUs granted to Executive Directors and certain senior employees autilization request providing for the draw down of an amount under the LTIP are exercisable subject to certain performance and equal to $100million under the RCF.
Shire will provide funding for the announced combination with In respect of any award granted to Executive Directors and certain Baxalta.
On January 11, 2016, Shire entered into an $18 billion senior employees under the LTIP, the performance criteria are bridge facilities agreement with certain financial institutions related based on product sales and Non GAAP ENITDA targets with a to the announced combination with Baxalta.
As at February 23, Non GAAP Adjusted ROIC underpin.
In respect of any award 2016, the bridge facilities agreement was undrawn.
granted to Executive Directors and certain senior employees under 22 First time adoption of FRS 102 the PSP Part B, performance criteria are based on growth in Non Reconciliations and descriptions of the effect of the transition to GAAP Adjusted ROIC and Non GAAP EBITDA.
FRS 102 on: i equity at the date of transition to FRS 102: ii equity RSUs and PSAs granted to employees below Executive Director at the end of the comparative period: and iii profit or loss for the and Executive Vice President level are not subject to performance comparative period reported under previous UK GAAP are given conditions and are only subject to service conditions with the below: exception of a select Group of senior employees.
Reconciliations of equity 2015 2015 2014 2014 January 1, December 31, Options WAEP Options WAEP 2014 2014 No $ No $ Note $M $M Outstanding at Equity as previously reported January 1, 2015 151,568 under previous UK GAAP 10,474.1 12,058.9 Granted during the year Deferred financing charge 22A 1.6 Forfeited during the year 68,969 Equity reported under Exercised during the year 82,599 FRS102 10,474.1 12,057.3 Expired during the year Reconciliations of profit or loss Outstanding at Year ended December 31, 2015 December 31, Exercisable at 2014 December 31, 2015 Note $M Profit as previously reported under previous The weighted average fair value of options granted in the year UKGAAP 1,481.5 wasdetermined using the Black-Scholes option pricing model.
The Black-Scholes model is considered to apply the most Deferred financing charge 22A 1.6 appropriate valuation method due to the relatively short Profit reported under FRS 102 1,479.9 contractual lives of the options and the requirement to exercise within a short period after the employee becomes entitled to the 22A Deferred finance charges shares the vesting date.
Under FRS102, deferred financing charges which relate to a facility which has had a substantial modification should be extinguished.
The expected life used in the model has been adjusted, based on managements best estimate, for the effect of non-transferability, The Revolving Credit Facility RCF of Shire was initiated in 2010 and significantly modified in December 2014 when the terms of exercise restrictions, and behavioral considerations.
Non-vesting conditions and market conditions are taken into account when estimating the fair value of the option at grant date.
At December 31, 2014 there were $1.6million of fees which have been capitalized and were being amortized over the life of the facility.
Service conditions and non-market performance conditions are taken into account by adjusting the number of options expected Under FRS102, these capitalized fees should be written offat the date of the significant modification of the facility.
The comparative tovest at each reporting date.
figures for the 2014 year end have therefore been updated to reflect As at December 31, 2015 there were no options to subscribe for the expense of these costs in the year ending December 31, 2014.
Ordinary shares of 5p each, which remained exercisable.
Shire Annual Report 2015 187 Trademarks The following are trademarks either owned or licensed by Shire plc or its subsidiaries, which are the subject of trademark registrations in certain territories, or which are owned by third parties as indicated and referred to in this Annual Report: ADDERALL XR mixed salts of a single entity amphetamine NATPAR parathyroid hormone BUCCOLAM midazolam hydrochloride oromucosal solution NATPARA parathyroid hormone rDNA CALCICHEW trademark of Takeda Nycomed AS PENTASA trademark of Ferring B. V. Corp Ferring CARBATROL carbamazepine extended-release capsules PLENADREN hydrocortisone, modified release tablet CINRYZE C1 esterase inhibitor [human] QUILLIVANT trademark of Next Wave Pharmaceuticals, Inc. DAYTRANA trademark of Noven Pharmaceutical Inc. Noven REMINYL galantamine hydrobromide United Kingdom UK and Republic of Ireland trademark of Johnson & Johnson DERMAGRAFT trademark of Organogenesis Inc. J&J, excluding UK and Republic of Ireland Organogenesis REGPARA cinacalcet HCl ELAPRASE idursulfase REPLAGAL agalsidase alfa ELVANSE lisdexamfetamine dimesylate RESOLOR prucalopride ELVANSE ADULT lisdexamfetamine dimesylate REVESTIVE teduglutide ESTRACE trademark of Trimel Pharmaceuticals Inc. SENSIPAR cinacalcet HCl EXPUTEX trademark of Phoenix Labs TYVENSE lisdexamfetamine dimesylate FIRAZYR icatibant VANCOCIN trademark of ANI Pharmaceuticals Inc. FOSRENOL lanthanum carbonate VENVANSE lisdexamfetamine dimesylate GATTEX teduglutide [rDNA origin] VPRIV velaglucerase alfa INTUNIV guanfacine extended release VYVANSE lisdexamfetamine dimesylate KALBITOR ecallantide XAGRID anagrelide hydrochloride LIALDA trademark of Nogra International Limited ZEFFIX trademark of GSK MEZAVANT trademark of Giuliani International Limited 3TC trademark of GSK MIMPARA cinacalcet HCl 188 Shire Annual Report 2015 Designed and produced by MerchantCantos www.
com Print managed by urbanprintsupport.
co. uk Printed by Cousin, who have been Carbon Neutral since 2004 and have FSCchain of custody certification.
They also use vegetable-based inks and have ISO14001 environmental accreditation.
This report is printed on Munken Polar Smooth Crisp White, whichis FSC accredited.
Shire plc Annual Report 2015 SHAPING WHATS NEXT Innovating and growing fast to create the leading global biotech company focused on rare diseases.
Shire plc 5 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
